- $294.05m
- $278.22m
- $25.87m
- 91
- 50
- 31
- 59
Annual income statement for NVE, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 21.4 | 27 | 38.3 | 29.8 | 25.9 |
| Cost of Revenue | |||||
| Gross Profit | 17.2 | 20.7 | 30.2 | 23 | 21.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 8.62 | 10.7 | 12.6 | 11.3 | 9.88 |
| Operating Profit | 12.7 | 16.3 | 25.6 | 18.5 | 16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 14.2 | 17.5 | 27.1 | 20.5 | 18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 11.7 | 14.5 | 22.7 | 17.1 | 15.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 11.7 | 14.5 | 22.7 | 17.1 | 15.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 11.7 | 14.5 | 22.7 | 17.1 | 15.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.42 | 3 | 4.7 | 3.54 | 3.11 |
| Dividends per Share |